Blood Transfusion Diagnostics Market (2025 - 2035)

Blood Transfusion Diagnostics Market Size, Growth Research Report By Product Type (Infectious Disease Testing, Blood Grouping Tests, Compatibility Testing, Nucleic Acid Testing), By Technique (Enzyme-Linked Immunosorbent Assay, Polymerase Chain Reaction, Chemiluminescent Immunoassay, Microbiological Techniques), By End User (Hospitals, Blood Banks, Diagnostic Laboratories, Academic Institutions) - Competitor Industry Analysis and Trends Forecast Till 2035
ID: MRFR/MED/0620-HCR
200 Pages
Nidhi Mandole, Rahul Gotadki
Last Updated: July 22, 2026
Blood Transfusion Diagnostics Market
Market Size
Forecast Period2025-2035
CAGR (2025-2035)6.72%
2025 Market SizeUSD 6.52 Billion
2035 Market SizeUSD 12.49 Billion
Key Players
Grifols S.A.
Bio-Rad Laboratories
QuidelOrtho
Immucor
Quotient Limited
Beckman Coulter
Trends
  • Rising Surgical and Trauma Transfusion Volumes
  • Mandatory Individual-Donor NAT Regulations
  • Blood-Bank Automation and Digital Connectivity
Opportunities
  • Point-of-Care Blood-Typing Devices
  • AI-Driven Antibody Identification
  • Emerging-Market Blood-Bank Modernization
Request Free Sample

Blood Transfusion Diagnostics Market Summary

The Blood Transfusion Diagnostics Market stood at USD 6.52 billion in 2025 and is projected to reach USD 6.96 billion in 2026, climbing to USD 12.49 billion by 2035 at a CAGR of 6.72% during the forecast period. Rising surgical volumes worldwide and the WHO's push for 100% voluntary non-remunerated blood donation by 2030 are fueling demand for advanced screening and typing platforms [1]. Government-led blood safety programs — including the U.S. FDA's updated guidance on pathogen-reduction technologies and the EU Blood Directive revision — have created a regulatory tailwind that shows no signs of easing.

Legacy manual tube testing is giving way to fully automated column-agglutination and solid-phase platforms that cut turnaround times from hours to minutes. Nucleic acid testing (NAT) adoption for HIV, HBV, and HCV screening has accelerated after multiple countries mandated individual-donor NAT, with global spending on transfusion-related molecular testing exceeding USD 1.8 billion in 2024 [2]. These shifts are transforming blood banks from labor-intensive operations into digitally connected laboratories.

North America commands roughly 38% of the Blood Transfusion Diagnostics Market, underpinned by strict FDA mandates and high procedural volumes across the American Red Cross network. Asia-Pacific is the fastest-growing region at an estimated CAGR of 8.4%, driven by expanding blood-bank infrastructure in China and India. Europe holds the second-largest share at approximately 28%, anchored by harmonized EU screening protocols. The decade ahead will be shaped by automation, point-of-care adoption, and emerging-market capacity building.

 

Key Report Takeaways

• By Product Type

  • Consumables account for over 62% of the Blood Transfusion Diagnostics Market, driven by recurring reagent demand across blood banks globally.
  • Instruments are expanding at the fastest segment CAGR of 7.8%, as hospitals replace aging manual systems with automated analyzers.

• By Technology

  • Serology platforms dominate technology share, representing roughly USD 4.1 billion in 2025 revenue.
  • Nucleic acid tests are the fastest-growing technology in the Blood Transfusion Diagnostics Market, projected to grow at 8.3% CAGR through 2035.

• By Region

  • North America leads the Blood Transfusion Diagnostics Market with a 38% revenue share, followed by Europe at 28%.
  • Asia-Pacific is projected to register the highest regional CAGR of 8.4% through 2035.

 

Market Size and Forecast (2021–2035)

Market Research Future's estimates draw on primary interviews with blood bank directors, laboratory procurement officers, and transfusion medicine specialists across 22 countries, triangulated with company filings and WHO Global Status Reports on Blood Safety.

Blood Transfusion Diagnostics Market Size and Forecast
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Driver Impact Analysis

Driver ~% Impact on CAGR Geographic Relevance Impact Timeline
Rising surgical and trauma transfusion volumes +1.4% Global Long-term (≥4 yr)
Mandatory individual-donor NAT regulations +1.2% North America, Europe Short-term (≤2 yr)
Blood-bank automation and digital connectivity +1.0% North America, Asia-Pacific Medium-term (2–4 yr)
Expansion of voluntary blood-donation programs +0.8% Asia-Pacific, Africa Long-term (≥4 yr)
Pathogen-reduction technology adoption +0.7% Europe, North America Medium-term (2–4 yr)
Growth of organ transplant and oncology procedures +0.6% Global Long-term (≥4 yr)
Point-of-care and rapid-test development +0.5% Asia-Pacific, South America Medium-term (2–4 yr)

 

Rising Surgical and Trauma Transfusion Volumes

According to predictions from the Lancet Commission, there were more than 350 million surgical procedures performed worldwide in 2024. Every procedure that calls for a transfusion starts a series of pre-transfusion tests [3]. According to survey statistics, trauma centers in the United States alone used more than 13.6 million red blood cell units in 2024. The blood transfusion diagnostics market has a non-cyclical revenue floor that is mainly immune to recession due to this ongoing procedural need.

Mandatory Individual-Donor NAT Regulations

U.S. blood centers are being pushed to modernize multiplex NAT platforms by the FDA's 2023 final guidance, which adds individual-donor NAT for Zika virus screening to the current HIV/HCV/HBV regulations [2]. Adopted in 2024, the European Commission's updated Blood, Tissues and Cells regulation standardized pathogen-screening practices throughout its 27 member states. The addressable reagent and instrument base for NAT vendors in the blood transfusion diagnostics market is directly increased by these regulatory initiatives.

Blood-Bank Automation and Digital Connectivity

Japan's Red Cross completed a USD 420 million automation overhaul of its 55 regional blood centers between 2021 and 2024, replacing manual gel-card readers with fully integrated robotic lines [9]. Similar projects in Saudi Arabia and Brazil are underway. Automation reduces human error, cuts labor costs by an estimated 25–30%, and generates digital audit trails demanded by regulators — making it a triple incentive for the Blood Transfusion Diagnostics Market.

Expansion of Voluntary Blood-Donation Programs

WHO data shows that only 57% of low-income countries achieve 100% voluntary non-remunerated donation [1]. India's National Blood Transfusion Council allocated INR 1,200 crore (≈ USD 143 million) for 2024–2028 to modernize 3,200 blood banks, each requiring screening and typing reagents [7]. Africa's blood-collection deficit — estimated at 4 million units annually — presents a parallel growth vector for the Blood Transfusion Diagnostics Market as NGO and government funding scales up.

 

Restraints Impact Analysis

The restraint estimates below follow the same directional methodology described in Section 4 and are not directly subtractable from the headline CAGR.

Restraint ~% Impact on CAGR Geographic Relevance Impact Timeline
High capital cost of automated platforms −0.6% Asia-Pacific, Africa Short-term (≤2 yr)
Cold-chain and reagent stability challenges −0.5% Africa, South America Long-term (≥4 yr)
Shortage of trained transfusion technologists −0.4% Global Medium-term (2–4 yr)
Reimbursement pressure on blood-bank budgets −0.3% North America, Europe Medium-term (2–4 yr)
Regulatory fragmentation across emerging markets −0.3% Asia-Pacific, MEA Long-term (≥4 yr)

 

High Capital Cost of Automated Platforms

Many mid-tier hospitals in underdeveloped nations cannot afford a fully automated blood-typing and screening line, which can cost more than USD 1.2 million [12]. This obstacle is somewhat mitigated by leasing and reagent-rental arrangements, but facilities with limited funding in Southeast Asia and Sub-Saharan Africa continue to use manual tube testing, which slows conversion rates in the blood transfusion diagnostics market.

Cold-Chain and Reagent Stability Challenges

The majority of serological reagents need to be stored between 2 and 8 °C, while several NAT kits require temperatures below 20 °C. Reagent waste rates can be as high as 15–20% in tropical areas with unstable cold-chain infrastructure [13]. This increases the cost of each test and restricts the geographic reach of high-end diagnostic platforms, especially in rural areas where blood is collected in the blood transfusion diagnostics market.

Shortage of Trained Transfusion Technologists

The AABB estimates a 12% vacancy rate among U.S. blood-bank technologists, while European and Asian facilities face similar shortfalls [14]. This workforce gap slows instrument adoption and increases error risk, restraining growth in the Blood Transfusion Diagnostics Market even where capital budgets are sufficient.

 

Blood Transfusion Diagnostics Market Opportunities

Point-of-Care Blood-Typing Devices

Handheld and cartridge-based ABO/Rh typing devices are moving from prototype to commercialization, targeting military field hospitals, remote clinics, and emergency departments [8]. The addressable opportunity exceeds USD 600 million by 2032, creating a new product tier within the Blood Transfusion Diagnostics Market.

AI-Driven Antibody Identification

Machine-learning algorithms trained on millions of antibody panel results can reduce complex identification workflows from hours to minutes. At least three major vendors demonstrated AI-enabled platforms at AABB 2024 [17]. Licensing these algorithms as cloud-based SaaS modules opens a recurring-revenue stream for the Blood Transfusion Diagnostics Market.

Emerging-Market Blood-Bank Modernization

Africa and South Asia collectively need over 8,000 new or upgraded blood-bank facilities by 2030 to meet WHO targets [1]. Governments and multilateral donors — including the Global Fund and Gavi — are earmarking transfusion infrastructure grants, generating greenfield procurement opportunities in the Blood Transfusion Diagnostics Market.

Data Monetization Through Hemovigilance Platforms

Digital blood-management systems capture donor demographics, adverse-reaction data, and supply-chain analytics. Aggregated and de-identified, these datasets have value for epidemiological surveillance, health-economic modeling, and pharma R&D partnerships [18]. This data-monetization layer represents a high-margin adjacency for established players in the Blood Transfusion Diagnostics Market.

Pathogen-Reduction as a Screening Alternative

Pathogen-reduction technologies that inactivate a broad spectrum of pathogens could eventually simplify or replace certain screening steps, shifting spend from reagent-heavy testing to device-centric inactivation [10]. Early regulatory traction in Europe signals a potential market realignment worth monitoring over the next five years.

 

Blood Transfusion Diagnostics Market Future Outlook

AI and Machine-Learning Integration

By 2030, at least 40% of high-volume blood banks are expected to deploy AI-assisted antibody identification and inventory optimization tools [17]. These systems will reduce technologist workload by an estimated 35%, addressing workforce shortages while improving patient safety across the Blood Transfusion Diagnostics Market.

Platform Consolidation and Reagent-Rental Economics

The instrument market is shifting toward reagent-rental models where hospitals receive analyzers at no upfront cost in exchange for multi-year consumable contracts. This "razor-and-blade" approach lowers adoption barriers and locks in recurring revenue, reshaping competitive dynamics in the Blood Transfusion Diagnostics Market through 2035.

Molecular Typing and Extended Antigen Profiling

Genotyping-based blood-group determination — covering 300+ antigens versus the 30–40 detectable by serology — is poised to move from reference laboratories into routine use [21]. Falling sequencing costs and FDA clearance of multiplex genotyping panels will create a premium-testing tier within the Blood Transfusion Diagnostics Market.

Sustainability and Green Blood Banking

Blood banks generate substantial single-use plastic waste from test cards, cassettes, and reagent packaging. ESG-conscious procurement policies in Europe and North America are pushing vendors to develop recyclable consumables and carbon-neutral manufacturing [22]. Sustainability credentials are becoming a competitive differentiator in the Blood Transfusion Diagnostics Market.

 

Blood Transfusion Diagnostics Market Segmentation

By Product Type

Segment Metric Primary Demand Driver
Consumables 62% share (2025) Recurring reagent and test-card procurement
Instruments 7.8% CAGR (2026–2035) Automation upgrade cycle

 

Consumables dominate the Blood Transfusion Diagnostics Market because every transfusion episode requires fresh reagents regardless of installed instrument base. Gel cards, microplate reagents, and NAT assay kits form the bulk of recurring spend. Instruments, while a smaller share, are growing faster as hospitals replace decade-old manual platforms with fully automated column-agglutination and solid-phase systems that process 200+ samples per hour.

By Technology

Segment Metric Primary Demand Driver
Serology USD 4.10 B (2025) Established gold standard for routine typing
Nucleic Acid Tests 8.3% CAGR (2026–2035) Regulatory mandates for pathogen screening
Other Technologies 10% share (2025) Genotyping and emerging molecular platforms

 

Serology remains the workhorse of the Blood Transfusion Diagnostics Market, handling ABO/Rh typing, antibody screening, and crossmatching across most facilities worldwide. Nucleic acid tests are gaining share rapidly as countries mandate individual-donor NAT to close the serological window period for HIV, HBV, HCV, and emerging pathogens. Multiplex NAT platforms now screen for up to six pathogens in a single run, reducing per-test costs by approximately 20% compared to singleplex alternatives [2].

By Application

Segment Metric Primary Demand Driver
Disease Screening 55% share (2025) Regulatory mandates for transfusion-transmitted infections
Blood Group Typing 7.4% CAGR (2026–2035) Growing surgical volumes and extended antigen panels

 

Disease screening holds a majority share in the Blood Transfusion Diagnostics Market because every donated unit must pass through mandatory infectious-disease panels before release. Blood group typing is catching up as extended phenotyping and genotyping expand the testing menu beyond basic ABO/Rh.

By End User

Segment Metric Primary Demand Driver
Hospitals 45% share (2025) In-house blood banks and emergency departments
Diagnostic Laboratories USD 2.48 B (2025) Reference testing and centralized screening
Other End Users 6.1% CAGR (2026–2035) Blood centers, military, and mobile collection units

 

Hospitals anchor the end-user landscape of the Blood Transfusion Diagnostics Market, as most pre-transfusion testing occurs at bedside or in hospital blood banks. Diagnostic laboratories — particularly large centralized facilities operated by national blood services — process the highest volumes per site.

 

Regional Market Share Analysis

Region Metric Primary Investment Themes
North America 38% share (2025) FDA mandates, automation upgrades
Europe 28% share (2025) EU Blood Directive harmonization
Asia-Pacific 8.4% CAGR (2026–2035) Blood-bank build-out, NAT adoption
South America USD 0.39 B (2025) Voluntary donation expansion
Middle East & Africa USD 0.37 B (2025) Infrastructure investment, NGO programs
Total USD 6.52 B (2025) —

The Blood Transfusion Diagnostics Market spans five major regions, each shaped by distinct regulatory frameworks, blood-collection infrastructure, and healthcare spending patterns.

 

North America

Country Metric Key Driver
US 82% of regional share FDA NAT mandates, American Red Cross network
Canada 12% of regional share Canadian Blood Services modernization
Mexico 6% of regional share COFEPRIS regulatory upgrades

 

The U.S. anchors the Blood Transfusion Diagnostics Market in North America through the world's most stringent pre-transfusion testing requirements. FDA oversight of blood establishments, combined with AABB accreditation standards, ensures high per-test spending. Canada's centralized blood system is investing CAD 280 million in next-generation screening platforms through 2028 [19].

Europe

Country Metric Key Driver
Germany 7.2% CAGR Paul-Ehrlich-Institut standards
UK USD 0.32 B (2025) NHSBT automation program
France 16% of regional share EFS centralized testing network
Italy 12% of regional share Regional blood-center consolidation
Spain 6.5% CAGR NAT mandate implementation
Nordic Countries 8% of regional share High voluntary donation rates
Russia 5.9% CAGR Federal blood-service modernization
Rest of Europe 14% of regional share EU directive compliance spending

 

Europe's Blood Transfusion Diagnostics Market benefits from the revised EU Blood, Tissues and Cells regulation, which mandates pathogen screening harmonization across all member states by 2027 [5]. The UK's NHSBT invested GBP 95 million in automated testing lines at its 15 processing centers.

Asia-Pacific

Country Metric Key Driver
China 34% of regional share NMPA regulatory modernization
India 9.1% CAGR National Blood Transfusion Council funding
Japan USD 0.27 B (2025) Japanese Red Cross automation
South Korea 7.8% CAGR KFDA screening expansion
ASEAN 18% of regional share WHO-supported blood-safety programs
Rest of Asia-Pacific 6.9% CAGR Rising healthcare expenditure

 

Asia-Pacific is the fastest-growing region in the Blood Transfusion Diagnostics Market, propelled by government investment in blood-bank infrastructure. China's 14th Five-Year Plan allocated RMB 8.2 billion for blood-center upgrades across 31 provinces, while India's Ayushman Bharat program includes transfusion-safety provisions for 150,000 health sub-centers [7].

South America

Country Metric Key Driver
Brazil 58% of regional share Hemocentro network expansion
Argentina USD 0.07 B (2025) ANMAT regulatory upgrades
Rest of South America 7.3% CAGR Pan American Health Organization grants

 

Brazil's network of 32 Hemocentros and 2,500 collection posts drives over half of South America's demand in the Blood Transfusion Diagnostics Market. PAHO technical assistance programs are helping smaller nations adopt WHO-recommended screening algorithms [20].

Middle East & Africa

Country Metric Key Driver
Saudi Arabia 28% of regional share Vision 2030 healthcare investment
UAE 7.6% CAGR Hub strategy for medical tourism
South Africa USD 0.08 B (2025) SANBS modernization
Egypt 22% of regional share National Blood Transfusion Service upgrades
Rest of MEA 6.2% CAGR Global Fund and NGO procurement

 

The Middle East & Africa region in the Blood Transfusion Diagnostics Market faces acute infrastructure gaps: Sub-Saharan Africa collects only 5 units per 1,000 population versus the WHO-recommended minimum of 10 [1]. Saudi Arabia's Vision 2030 health reforms and the UAE's hospital expansion drive premium-segment demand.

 

Blood Transfusion Diagnostics Market By Region, 2025-2035

Competitive Benchmarking

The Blood Transfusion Diagnostics Market exhibits medium concentration, with the top five companies holding an estimated 55–62% combined revenue share. The Herfindahl-Hirschman Index (HHI) sits in the 1,200–1,500 range, indicating moderate competitive intensity. Long-term reagent-rental contracts and regulatory approvals create meaningful switching costs that protect incumbents while allowing specialized niche players to thrive.

Company Est. Revenue Share Range Key Offerings for Blood Transfusion Diagnostics Market Strategic Positioning
Grifols S.A. ~14–18% WADiana automated platform; NAT screening systems Vertically integrated plasma and diagnostics leader
Bio-Rad Laboratories ~12–16% IH-500 and IH-1000 gel-card analyzers Broad immunohematology reagent portfolio
QuidelOrtho (Ortho Clinical Diagnostics) ~10–14% ORTHO VISION and ORTHO VISION Max analyzers Dominant in North American hospital segment
Immucor (Werfen) ~8–12% NEO Iris automated platform; PreciseType genotyping Integration of genotyping and serology
Quotient Limited ~4–7% MosaiQ microarray platform Disruptive multiplex testing approach
Beckman Coulter (Danaher) ~3–6% PK7300 automated system Leverages parent company's lab-automation ecosystem
BAG Healthcare ~2–4% ID-card and gel-card reagents Strong European distribution network
DiaSorin S.p.A. ~2–4% Molecular screening assays Cross-selling from infectious disease portfolio
Hemosonics (Stago) ~1–3% Quantra hemostasis platform Emerging player in perioperative blood management
Agena Biosciences (Bruker) ~1–3% MassARRAY genotyping system Precision genotyping for extended antigen panels

 

 

Recent News & Developments

  • Grifols (March 2025): Launched the WADiana Compact analyzer targeting mid-volume blood banks, expanding its addressable market in Asia-Pacific and South America [23].
  • Immucor/Werfen (July 2024): Completed integration of PreciseType molecular genotyping into the NEO Iris workflow, reducing hands-on time by 40% [26].
  • Bio-Rad Laboratories (April 2024): Announced a USD 150 million reagent-supply agreement with NHS Blood and Transplant covering 2025–2030 [27].
  • European Commission (December 2023): Adopted the revised Blood, Tissues and Cells regulation mandating harmonized pathogen screening across all EU member states by 2027 [5].
  • India NBTC (September 2023): Released an INR 1,200 crore funding blueprint to digitize and equip 3,200 blood banks nationwide by 2028 [7].

 

Blood Transfusion Diagnostics Market Report Scope

Parameter Detail
Market Scope Blood Transfusion Diagnostics Market — instruments, consumables, reagents, and software for pre-transfusion testing
Study Period 2021–2035
CAGR (2026–2035) 6.72%
Base-Year Market Size USD 6.52 Billion (2025)
Forecast-End Market Size USD 12.49 Billion (2035)
Fastest Growing Segment Nucleic Acid Tests (by technology); Asia-Pacific (by region)
Companies Profiled 10 (Grifols, Bio-Rad, QuidelOrtho, Immucor, Quotient, Beckman Coulter, BAG Healthcare, DiaSorin, Hemosonics, Agena Biosciences)
Valuation Currency USD (constant 2025 dollars)

 

 

FAQs

How does reagent-rental pricing compare to outright instrument purchase for mid-size hospitals?
Reagent-rental eliminates USD 0.8–1.2 million upfront capital by bundling analyzer placement with multi-year consumable contracts. Per-test costs run 10–15% higher than ownership models, but total cost of ownership often favors rental when maintenance is included [12].
What cybersecurity risks do connected blood-bank information systems face?
Networked blood-management systems are vulnerable to ransomware that can freeze donor records and disrupt workflows. The U.S. HHS flagged blood centers as critical infrastructure in 2024, urging adoption of zero-trust architectures [15].
How are genotyping panels disrupting traditional serological crossmatching?
Multiplex genotyping identifies 300+ red-cell antigens from a single DNA sample, reducing alloimmunization risk in chronically transfused patients. Costs have fallen below USD 50 per panel, making routine use feasible in tertiary centers [21].
Which accreditation standards most influence purchasing decisions?
AABB accreditation and ISO 15189 certification drive procurement specifications in most markets. Analyzers lacking compatibility with these frameworks face exclusion from hospital tenders [4].
What role do public-private partnerships play in African blood-bank expansion?
The Global Fund and Gavi co-finance screening equipment procurement in 38 Sub-Saharan countries. These partnerships reduce per-unit screening costs by pooling reagent procurement across nations [16].
How will pathogen-reduction adoption affect screening reagent demand?
Broad-spectrum inactivation could eventually reduce the number of mandatory serological tests per unit. Near-term impact is limited because regulators still require parallel screening alongside inactivation [10].
What integration challenges arise when upgrading from manual to automated platforms?
Legacy LIS interfaces often lack HL7 FHIR compatibility, requiring middleware investment of USD 50,000–150,000 per site. Staff retraining typically adds 3–6 months before full throughput is achieved [9].    
Author
Author
Author Profile
Nidhi Mandole LinkedIn
Senior Research Analyst
She is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Nidhi is comfortably versed in data centric research backed by healthcare educational background. She leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. Her key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, she showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed hematology and transfusion medicine journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), European Medicines Agency (EMA) Blood Products Working Party, AABB (Association for the Advancement of Blood & Biotherapies), CDC Division of Healthcare Quality Promotion (Blood Safety Surveillance), National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI), National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) Department of Essential Health Services (Blood Transfusion Safety), European Centre for Disease Prevention and Control (ECDC) Blood Safety Database, EU Directorate-General for Health and Food Safety (SANTE), America's Blood Centers (ABC), International Society of Blood Transfusion (ISBT), national blood service reports (NHS Blood and Transplant UK, Centers for Disease Control and Prevention Blood Safety Surveillance, EU member state competent authorities), and blood bank accreditation bodies (AABB, FACT, Joint Commission). These sources were used to collect blood donation statistics, infectious disease screening protocols, regulatory approval pathways for serological and NAT testing, blood group typing technology adoption rates, and hematological disease prevalence data.

 

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consist of CEOs, VPs of R&D, regulatory affairs chiefs, quality assurance directors, and commercial directors from in-vitro diagnostic manufacturers, blood screening reagent producers, and analytical instrument OEMs. Blood bank medical directors, transfusion medicine specialists, hematopathologists, clinical laboratory scientists, hospital transfusion service coordinators, and procurement leads from hospital blood banks, independent donor centers, reference laboratories, and academic medical centers comprised demand-side sources. Market segmentation was validated across infectious disease screening and immunohematology testing through primary research. Product pipeline timelines for multiplex assays and automated blood grouping platforms were confirmed, and clinical adoption patterns of molecular typing technologies, reagent pricing strategies, and blood bank operational budgets were gathered.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (32%), Others (40%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

 

Market Size Estimation

Global market valuation was derived through revenue mapping and testing volume analysis across immunohematology and infectious disease screening segments. The methodology included:

Identification of 50+ key diagnostic manufacturers and reagent suppliers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across blood grouping serology, cross-matching compatibility testing, nucleic acid testing (NAT) for viral markers (HIV, HBV, HCV), and automated immunohematology analyzers

Analysis of reported and modeled annual revenues specific to transfusion diagnostics portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (test volume × ASP by country/region, segmented by blood bank testing algorithms) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations for reagents, instruments, and software solutions

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.